Systematic review and meta-analysis of anti-CD20 treatments in patients with COVID-19: an assessment of severe illness and mortality outcomes.
Chia Siang Chia KowDinesh Sangarran RamachandramSyed Shahzad HasanKaeshaelya ThiruchelvamPublished in: Inflammopharmacology (2023)
Healthcare practitioners should exercise caution when prescribing these anti-CD20 monoclonal antibodies during the COVID-19 pandemic to patients who are indicated for these agents, particularly those with underlying conditions like multiple sclerosis or rheumatoid arthritis.
Keyphrases
- multiple sclerosis
- rheumatoid arthritis
- healthcare
- primary care
- end stage renal disease
- ejection fraction
- newly diagnosed
- high intensity
- physical activity
- prognostic factors
- early onset
- cardiovascular events
- emergency department
- risk factors
- disease activity
- general practice
- patient reported outcomes
- skeletal muscle
- metabolic syndrome
- body composition
- idiopathic pulmonary fibrosis
- interstitial lung disease
- drug induced
- insulin resistance
- adverse drug
- weight loss
- health insurance